neratinib
E902878
EGFR inhibitor
HER2 inhibitor
antineoplastic agent
orally administered drug
small molecule drug
tyrosine kinase inhibitor
Neratinib is an oral tyrosine kinase inhibitor used primarily in the treatment of HER2-positive breast cancer, often as extended adjuvant therapy after trastuzumab.
All labels observed (1)
| Label | Occurrences |
|---|---|
| neratinib canonical | 4 |
How this entity was disambiguated
This entity first appeared as the object of triple T11074261 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: neratinib Context triple: [HER2 receptor, targetOfDrug, neratinib]
-
A.
Ibrance
Ibrance is a targeted oral cancer medication (palbociclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative advanced or metastatic breast cancer.
-
B.
pertuzumab
Pertuzumab is a monoclonal antibody used in targeted therapy for HER2-positive breast cancer, often administered alongside trastuzumab and chemotherapy.
-
C.
Zaltrap
Zaltrap is a cancer medication (brand name for aflibercept) used primarily in combination chemotherapy to treat metastatic colorectal cancer by inhibiting vascular endothelial growth factor (VEGF).
-
D.
larotrectinib
Larotrectinib is a targeted cancer therapy that selectively inhibits TRK fusion proteins and is used to treat solid tumors harboring NTRK gene fusions regardless of tumor site.
-
E.
Libtayo
Libtayo is a monoclonal antibody immunotherapy drug used primarily to treat certain types of advanced skin and lung cancers by targeting the PD-1 pathway.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: neratinib Target entity description: Neratinib is an oral tyrosine kinase inhibitor used primarily in the treatment of HER2-positive breast cancer, often as extended adjuvant therapy after trastuzumab.
-
A.
Ibrance
Ibrance is a targeted oral cancer medication (palbociclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative advanced or metastatic breast cancer.
-
B.
pertuzumab
Pertuzumab is a monoclonal antibody used in targeted therapy for HER2-positive breast cancer, often administered alongside trastuzumab and chemotherapy.
-
C.
Zaltrap
Zaltrap is a cancer medication (brand name for aflibercept) used primarily in combination chemotherapy to treat metastatic colorectal cancer by inhibiting vascular endothelial growth factor (VEGF).
-
D.
larotrectinib
Larotrectinib is a targeted cancer therapy that selectively inhibits TRK fusion proteins and is used to treat solid tumors harboring NTRK gene fusions regardless of tumor site.
-
E.
Libtayo
Libtayo is a monoclonal antibody immunotherapy drug used primarily to treat certain types of advanced skin and lung cancers by targeting the PD-1 pathway.
- F. None of above. chosen
Statements (49)
| Predicate | Object |
|---|---|
| instanceOf |
EGFR inhibitor
ⓘ
HER2 inhibitor ⓘ antineoplastic agent ⓘ orally administered drug ⓘ small molecule drug ⓘ tyrosine kinase inhibitor ⓘ |
| administeredWithFood | yes ⓘ |
| belongsToClass | pan-HER inhibitors ⓘ |
| bindsCovalentlyTo |
EGFR kinase domain
ⓘ
linked to:
EGFR
HER2 kinase domain ⓘ |
| contraindication | severe hepatic impairment ⓘ |
| developer | Puma Biotechnology ⓘ |
| drugInteraction |
strong CYP3A4 inducers
ⓘ
strong CYP3A4 inhibitors ⓘ |
| eliminationRoute | fecal ⓘ |
| hasApprovalYear | 2017 ⓘ |
| hasATCCode | L01EB03 ⓘ |
| hasBlackBoxWarning | diarrhea risk ⓘ |
| hasCASNumber | 698387-09-6 ⓘ |
| hasCommonAdverseEffect |
abdominal pain
ⓘ
decreased appetite ⓘ diarrhea ⓘ fatigue ⓘ nausea ⓘ rash ⓘ stomatitis ⓘ vomiting ⓘ |
| hasDosageForm | oral tablet ⓘ |
| hasDosingSchedule | once daily ⓘ |
| hasINN | neratinib ⓘ |
| hasMolecularFormula | C30H29ClN6O3 ⓘ |
| hasRouteOfAdministration | oral ⓘ |
| hasSeriousAdverseEffect |
hepatotoxicity
ⓘ
severe diarrhea ⓘ |
| hasUSBrandName | Nerlynx ⓘ |
| indication |
HER2-positive breast cancer
ⓘ
adjuvant therapy after trastuzumab-based treatment ⓘ extended adjuvant treatment of early-stage HER2-positive breast cancer ⓘ |
| mechanismOfAction | irreversible pan-HER tyrosine kinase inhibition ⓘ |
| metabolism | CYP3A4-mediated ⓘ |
| regulatoryApproval |
EMA-approved
ⓘ
FDA-approved ⓘ |
| requiresMonitoring | liver function tests ⓘ |
| requiresProphylaxis | antidiarrheal medication ⓘ |
| targets |
EGFR
ⓘ
ERBB1 ⓘ
linked to:
EGFR
ERBB2 ⓘ HER2 ⓘ
linked to:
ERBB2
|
| usedAs | extended adjuvant therapy ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: neratinib Description of subject: Neratinib is an oral tyrosine kinase inhibitor used primarily in the treatment of HER2-positive breast cancer, often as extended adjuvant therapy after trastuzumab.
Referenced by (4)
Full triples — surface form annotated when it differs from this entity's canonical label.